Literature DB >> 22016074

Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial.

Renee M Sullivan1, Andrea M Russo, Kellie Chase Berg, Kira Q Stolen, Milan Seth, David Perschbacher, John D Day, Brian Olshansky.   

Abstract

BACKGROUND: Appropriate implantable cardioverter-defibrillator (ICD) therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF) depends, in part, on the programming of tachycardia zones.
OBJECTIVE: We assessed events treated with ICD shocks or antitachycardia pacing (ATP) in the Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs (INTRINSIC RV) trial.
METHODS: ATP and shock episodes from 1530 patients with dual-chamber ICDs were analyzed.
RESULTS: For episodes in which electrograms were stored and adjudicated, ATP was delivered for 763 episodes (182 patients), shock-only was delivered for 300 episodes (146 patients), and shock following ATP was delivered for 81 episodes (56 patients). ATP was delivered appropriately for 507 episodes (130 patients), with 93% success, and inappropriately for 256 episodes (89 patients). For ATP episodes, appropriate (VT: 170 ± 28 bpm) and inappropriate (not VT: 165 ± 21 bpm) rates did not differ (P = .16). When the initial therapy was shock, onset rates were higher for appropriate therapy than for inappropriate therapy (224 ± 46 bpm vs 187 ± 31 bpm; P <.001). Inappropriate ATP was more likely to be followed by a shock (odds ratio 2.49; 95% confidence interval 1.56-3.97; P <.001). Fifty-eight percent (225 of 381) of shocked episodes had rates <200 bpm. For episodes between 200 and 250 bpm, 20% (23 of 113) were polymorphic VT or VF, 59% were monomorphic VT, 19% were supraventricular, and <1% was artifact. For episodes >250 bpm, 37% were VF, 28% polymorphic VT, 23% monomorphic VT, 7% supraventricular, and 5% artifact.
CONCLUSIONS: In a general ICD population, ATP treated VT effectively or obviated the need for shock. Most ventricular arrhythmias <250 bpm were not VF. Proper zone programming may identify and treat VT without shock. Copyright Â
© 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22016074     DOI: 10.1016/j.hrthm.2011.10.018

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  1 in total

1.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesœs Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  J Arrhythm       Date:  2016-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.